

A Study of Symptomatology of COVID-19 Laboratory-Confirmed Cases at Tertiary Care Center: A Cross-Sectional Study.

Article Metadata

Authors: Dabhekar S, Basagoudanavar S, Bidkar V, Prathipati K, Sujiv A, Rathod BS, Gadwal D

Journal: Cureus

Year: 2022

Volume/Issue: 14/2

PMID: 35308685

DOI: 10.7759/cureus.22186

PubMed URL: <https://ncbi.nlm.nih.gov/pubmed/35308685>

Full Text (from PubMed Central)

<https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/>

[oai:pubmedcentral.nih.gov:8925989](https://pubmedcentral.nih.gov/8925989)

Epidemiology/Public Health

A Study of Symptomatology of COVID-19 Laboratory-Confirmed Cases at Tertiary Care Center: A Cross-Sectional Study

sandyent@aiimsnagpur.edu.in

Copyright © 2022, Dabhekar et al.

<https://creativecommons.org/licenses/by/3.0/>

This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Background and objectives

People with coronavirus disease 2019 (COVID-19) have had a wide range of symptoms reported such as fever or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, a new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting and diarrhea. The severity of disease, mortality, symptoms of COVID-19 showed significant variation in different parts of the world. The purpose of this study was to describe epidemiological characteristics and symptoms of confirmed COVID-19 patients and to identify factors associated with the severity of the disease.

This is a cross-sectional descriptive study conducted on hospitalized COVID-19 patients from May 2020 to July 2020. We obtained data on the demographic characteristics, symptoms, and infection severity for 150 patients by pre-tested semi-structured interview. Information was recorded in a Microsoft Excel sheet and exported to SPSS Statistics (Armonk, NY: IBM Corp.) for analysis.

The median age of the patients was 31.5 years, where 42% of the patients were female; 52.7% of patients were symptomatic while 47.3% of patients were asymptomatic. Common symptoms at the time of admission were fever (40.5%), sore throat (36.7%), cough (32.9%), rhinitis (19.0%), and body ache (13.9%). At least one comorbidity was reported in 20.0% of the patients, with the most common comorbidity being hypertension (14.7%). History of contact with known confirmed cases of COVID-19 within the last 14 days was present in 94% of patients. The presence of any coexisting illness was significantly higher among patients with severe disease than among those with non-severe disease (80% vs. 17.9%, $p=0.012$).

High proportions of COVID-19 patients were asymptomatic in our study. Fever and cough were the most common symptoms. The presence of any coexisting illness was significantly higher among patients with severe disease than among those with a non-severe disease.

pmc-prop-legally-suppressed

pmc-prop-has-supplement

pmc-prop-suppress-copyright

pmc-prop-is-real-version

pmc-prop-is-scanned-article

The content published in Cureus is the result of clinical experience and/or research by independent individuals or organizations. Cureus is not responsible for the scientific accuracy or reliability of data or conclusions published herein. All content published within Cureus is intended only for educational, research and reference purposes. Additionally, articles published within Cureus should not be deemed

a suitable substitute for the advice of a qualified health care professional. Do not disregard or avoid professional medical advice due to content published within Cureus.

The first human cases of coronavirus disease 2019 (COVID-19), the disease caused by the novel coronavirus, subsequently named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were first reported by officials in Wuhan City, China, in December 2019. From December 30, 2019, through August 31, 2021, over 216 million COVID-19 cases and 4.5 million deaths have been reported globally [

On reviewing the literature, it has been found that severity of disease, mortality, and symptoms of COVID-19 show significant variation in different parts of the world. In India patients with respiratory symptoms are usually selected for viral testing. Various studies have shown that non-respiratory manifestations such as atrial fibrillation are also seen in COVID-19 [

We aimed to describe epidemiological characteristics and symptoms of patients confirmed to have COVID-19 disease and to identify factors associated with the severity of the disease. We hope our study findings will inform the global community of the spectrum of symptoms of this novel coronavirus.

Materials and methods

Study design and participants

This prospective cohort study was carried out from May 2020 to July 2020, at a tertiary care teaching hospital located in Central India and catering to both urban and rural populations. Study participants were all patients diagnosed and admitted with COVID-19, in a tertiary care hospital in central India from May 2020 to July 2020. Only laboratory-confirmed cases that were defined as positive based on the results of real-time reverse transcriptase-polymerase chain reaction (RT-PCR) assay of nasal and pharyngeal swab samples were included. The study was initiated following approval from the institutional ethics committee. Written informed consent was obtained from all the participants. A total of 150 patients who met the study criteria were included. During this period, all patients with RT-PCR test positive for COVID-19 with mild-to-moderate symptoms or even no symptoms were admitted to this hospital. Patients with severe symptoms (pulse oximeter oxygen saturation less than or equal to 80%) were not admitted because of the unavailability of a critical care unit in this newly developing hospital.

Data management and statistical analysis

A pre-tested semi-structured interview schedule was used for data collection. A team of doctors who had treated these patients extracted the recent exposure history, clinical symptoms, comorbidities, personal and past history from patients. All laboratory tests were performed according to treatment needs. Patients with COVID-19 having severe illness were defined as having one of the following criteria: (a) respiratory distress with a respiratory rate more than or equal to 30/min or (b) pulse oximeter oxygen saturation less than or equal to 93% at rest. Clinical characteristics were compared between severe and non-severe cases. Since relevant data for the Indian population was not available at the beginning of the study, sample size was not estimated. Hence, it was decided to estimate power at the end of the study.

Statistical analyses were performed with SPSS version 24.0 (Chicago, IL: IBM Corp.). Continuous variables are described as median values and interquartile ranges (IQRs), and categorical variables are reported as numbers and percentages. Fisher exact test was used to determine any associations between two categorical variables.

We obtained data on the demographic characteristics, symptoms, and outcomes for 150 patients hospitalized from in our hospital May 2020 to July 2020. The demographic and clinical characteristics of the patients are shown in Table

Demographic distribution and clinical characteristics of the study sample on admission

Sociodemographic characteristic

Contact history with a known confirmed case

Positive contact history

Positive travel history

Distribution of symptoms in symptomatic COVID-19 patients

COVID-19: coronavirus disease 2019

The most common symptom of COVID-19 was fever, which was observed in 40.5% (32/79) of the patients. The other common symptoms were sore throat (36.7%, 29/79), cough (32.9%, 26/79), rhinitis (19.0%, 15/79), body ache (13.9%, 11/79), new loss of smell (12.7, 10/79), breathlessness (10.1%, 8/79), and headache (10.1%, 8/79). Less common symptoms were new loss of taste (6.3%, 5/79), expectoration, diarrhea, nausea, and chills (1.3%, 1/79). At least one comorbidity was reported in 20.0% (30/150) of the patients, with the most common comorbidity being hypertension (14.7%, 22/150) followed by diabetes (4.7%, 7/150) and ischemic heart disease (2%, 3/150) as shown in Table

Frequency/percentage of comorbid conditions associated with COVID-19 patients

COVID-19: coronavirus disease 2019

Ischemic heart disease

Acquired immunodeficiency syndrome

History of contact with a known confirmed case of COVID-19 within the last 14 days was present in 94% (141/150) patients. A history of traveling (intra-country) in recent 15 days was present in 6.7% (10/150) patients. The severe group included five (3.3%) patients while the non-severe group included 145 (96.7%) patients. Patients with severe disease were older than those with a non-severe disease by a median of 14 years. The presence of any coexisting illness was significantly higher among patients

with severe disease than among those with non-severe disease (80% vs. 17.9%, $p=0.012$) which suggests a significant association of the presence of coexisting illness with the severity of COVID-19 as depicted in Table

Comparison between severe and non-severe COVID-19 disease group

COVID-19: coronavirus disease 2019

Severe disease, N (%)

Non-severe disease, N (%)

Understanding the clinical characteristics of COVID-19 in patients is very important for controlling the spread of COVID-19 and decision-making for epidemic control. In our study, we analyzed the symptoms of 150 patients with COVID-19. Among them, 52.7% of patients were symptomatic while 47.3% of patients were asymptomatic, which was consistent with the previous report in which it was 48.2% and 51.8%, respectively [

Available evidence indicates that up to 12% of transmission occurs before an index case develops symptoms [

In this study, the most common symptom of COVID-19 was fever, which was observed in 40.5% (32/79) of the patients, which was consistent with the previous report of Lechien et al. in which it was 45.4% [

Based on the current research, olfactory dysfunction has a high incidence rate in COVID-19 patients in some European and American countries, while it rarely occurs in Chinese patients [

In our study, approximately 6% of patients of COVID-19 had a loss of taste (ageusia). Lee et al. reported ageusia in 15.3% of patients [

In our study, the presence of any coexisting illness was significantly higher among patients with severe disease than among those with non-severe disease (80% vs. 17.9%, $p=0.012$) with estimated power at 80.6%. Guan et al. reported that multiple comorbidities are associated with the severity of COVID-19 disease progression. Many of the poorer outcomes for COVID-19 have been related to cardiovascular comorbid conditions [

Our study has some notable limitations. First, only non-critical cases of COVID-19 were admitted to our hospital because of shortage of infrastructure and non-availability of intensive critical care unit. So our study cohort may represent the milder end of COVID-19. Second, we included symptoms and other parameters only on the day of admission and there was no follow-up. So we might have missed some symptoms that developed late during hospitalization. This is a modest-sized case series of patients admitted to the hospital; a collection of standardized data for a larger cohort would help to further define the clinical presentation, natural history, and risk factors. Further studies in outpatient, primary care, or community settings are needed to get a full picture of the spectrum of clinical severity. Despite these

limitations, this study provides evidence on the main socio-demographic and clinical symptoms of confirmed cases of COVID-19.

Approximately half of the COVID-19 patients in our study were asymptomatic. Fever and cough were the most common symptoms. The presence of any coexisting illness was significantly higher among patients with severe disease than among those with a non-severe disease. Patients with severe disease were older than those with a non-severe disease.

We documented the epidemiological characteristics and clinical symptoms of COVID-19 among patients from Central India. In our study, hypertension and diabetes were the most common comorbidities. Patients of advanced age with comorbidities were found to have more severe diseases. Further extensive studies with larger sample sizes from different parts of the world are required to gain deeper insights into COVID-19, which would lead to a better characterization of the course of this disease.

The authors have declared that no competing interests exist.

Consent was obtained or waived by all participants in this study. Institutional Ethics Committee All India Institute of Medical Sciences, Nagpur issued approval IEC/Pharmac/89/2020

Weekly epidemiological update on COVID-19 - 31 August 2021

<https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---31-august-2021>

<https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html>

New-onset atrial fibrillation during COVID-19 infection predicts poor prognosis

10.5603/CJ.a2020.0145

Self-reported olfactory and taste disorders in patients with severe acute respiratory coronavirus 2 infection: a cross-sectional study

Clinical characteristics of coronavirus disease 2019 in China

10.1056/NEJMoa2002032

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China

Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America

Am J Respir Crit Care Med

10.1164/rccm.201908-1581ST

Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020

10.2807/1560-7917.ES.2020.25.10.2000180

Transmission of 2019-nCoV infection from an asymptomatic contact in Germany

COVID-19 transmission within a family cluster by presymptomatic carriers in China

Presymptomatic transmission of SARS-CoV-2 - Singapore, January 23-March 16, 2020

MMWR Morb Mortal Wkly Rep

10.15585/mmwr.mm6914e1

Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019

Risk factors for severe disease and efficacy of treatment in patients infected with COVID-19: a systematic review, meta-analysis, and meta-regression analysis

Clinical presentation of COVID-19: a systematic review focusing on upper airway symptoms

10.1177/0145561320920762

Features of anosmia in COVID-19

10.1016/j.medmal.2020.04.006

Anosmia and ageusia: common findings in COVID-19 patients

Association of chemosensory dysfunction and COVID-19 in patients presenting with influenza-like symptoms

Int Forum Allergy Rhinol

Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study

Eur Arch Otorhinolaryngol

10.1007/s00405-020-05965-1

Prevalence and duration of acute loss of smell or taste in COVID-19 patients

10.3346/jkms.2020.35.e174

Olfactory and gustatory dysfunctions in 100 patients hospitalized for COVID-19: sex differences and recovery time in real-life

Eur Arch Otorhinolaryngol

10.1007/s00405-020-06102-8

Cardiovascular comorbidity and its impact on patients with COVID-19

10.1183/13993003.01227-2020

Citation

Dabhekar S, Basagoudanavar S, Bidkar V, Prathipati K, Sujiv A, Rathod BS, Gadwal D. A Study of Symptomatology of COVID-19 Laboratory-Confirmed Cases at Tertiary Care Center: A Cross-Sectional Study.. Cureus. 2022. DOI: 10.7759/cureus.22186

This document was generated from PubMed Central (PMC) full-text for Component 3, Iteration fc60a3af-b6e7-4d96-93f2-3dd5dfd5280e. Source: Open-access article 8925989. This is a complete full-text article from PMC.